The Hemophilia Alliance was pleased to attend and support the recent National Hemophilia Foundation annual meeting in Washington, DC. One of the highlights was the annual award luncheon. A list of the award winners can be found below.
The Hemophilia Alliance is pleased to announce that we have signed a supply agreement with Biogen Idec for their recently approved ALPROLIX , the first long acting RFIX to be approved by the FDA.
Letter to Mary Wakefield to obtain more information about the audits that the Health Resources and Services Administration (HRSA) recently conducted to certify that covered entities are still eligible for the 340B Drug Pricing Program (340B Program).
OPA is required to recertify all participating covered entities enrolled in the 340B Program. All members should read this important recertification update.
